Cytokinetics Inc

B. Riley analyst Mayank Mamtani has identified six top biotech picks heading into third-quarter 2026 earnings season, following the Federal Reserve's 25 basis point rate hike to 4.00%, its first increase since July 2023. The unanimous 12-0 vote left room for one to two additional hikes before year-end, and with the 10-year Treasury at its highest level since 2007, small and mid-cap biotech stocks face a macro-driven drawdown that historically has presented buying opportunities. The XBI index is up 27% year-to-date but down 2% quarter-to-date, compared to the S&P 500's 13% and 4% gains respectively, while loss of exclusivity-driven pharma mergers and acquisitions track toward their strongest year since 2019, permanent FDA leadership is installed, and drug-pricing risk is largely resolved through most favored nation agreements covering 26 companies. Late third quarter and fourth quarter carry over 40 company-specific catalysts across the coverage list. The picks are Axsome Therapeutics, rated Buy with a $300 price target and up 6% year-to-date, where the analyst models AUVELITY revenue at approximately $205 million to $210 million against consensus of $215.8 million and total revenue of approximately $259 million; Cytokinetics, rated Buy with a $146 price target and up 4% year-to-date, with MYQORZO wholesale tracking to approximately $18 million for the full third quarter versus $8.9 million for all of second quarter; Eton Pharmaceuticals, rated Buy with a $70 price target and up 229% year-to-date, with consensus third-quarter 2026 and fiscal year 2026 revenue of $42 million and $149.7 million versus management's guidance of over $145 million for fiscal year 2026; Harrow, rated Buy with a $60 price target and down 31% year-to-date, with fiscal year 2026 guidance of $350 million to $365 million; TG Therapeutics, rated Buy with an $86 price target and up 95% year-to-date, positioned to compound off an approximately $1 billion U.S. Briumvi exit run-rate at year-end 2026; and Zymeworks, rated Buy with a $44 price target and up 4% year-to-date, where partner Jazz Pharmaceuticals' third-quarter 2026 report in early November provides the first commercial read on the first-line HER2-positive gastroesophageal adenocarcinoma launch following the August 25 approval and $250 million milestone.

Cytokinetics announced additional results from its ACACIA-HCM and MAPLE-HCM studies at the European Society of Cardiology Congress 2026, showing that aficamten improves cardiac structure and diastolic function in non-obstructive HCM and outperforms metoprolol across pre-trial treatment groups in obstructive HCM. The company plans to submit a supplemental new drug application for aficamten in nHCM in the fourth quarter of 2026, potentially expanding its market beyond the approved oHCM indication under the brand name Myqorzo. The FDA has already accepted Cytokinetics' sNDA for MAPLE-HCM, with a target action date of November 14, 2026. Myqorzo faces competition from Bristol Myers Squibb's Camzyos and Edgewise Therapeutics' EDG-7500, which is entering phase III in late 2026. Cytokinetics shares have gained 12.4% year to date, and the Zacks Consensus Estimate for 2026 loss per share has narrowed to $6 from $6.26 over the past 60 days.

Cytokinetics reported a second-quarter 2026 loss of $1.50 per share, narrower than the Zacks Consensus Estimate of a loss of $1.63 per share, while revenue of $28.6 million beat the $20 million consensus. Net product revenue from newly launched Myqorzo was $25.3 million, with U.S. sales of $23.0 million and initial European distributor purchases of $2.3 million in Germany. More than 700 U.S. prescribers had written Myqorzo by June 30, and the drug exited the quarter with over 40% new-to-brand prescription share in the cardiac myosin inhibitor category. The company raised its full-year 2026 GAAP R&D and SG&A expense guidance to $860–$890 million and ended the quarter with approximately $1.7 billion in cash following a May public offering that generated about $760.1 million in net proceeds.

The congestive heart failure market across the seven major markets was valued at USD 9 billion in 2025 and is projected to grow at a compound annual growth rate of 8% during the 2026 to 2036 forecast period, according to a new report from DelveInsight. The United States accounted for the largest share of the 7MM market in 2025, with nearly 7.4 million diagnosed prevalent cases out of approximately 21.1 million total diagnosed prevalent cases across the seven major markets. Growth is expected to be driven by the rising prevalence of cardiovascular diseases, an aging population, and the anticipated launch of emerging therapies such as Omecamtiv Mecarbil from Cytokinetics, Ziltivekimab from Novo Nordisk, CardiALLO Cell Therapy from BioCardia, and Umiposgene Parvec from Bayer. The report also highlights a robust clinical pipeline that includes candidates from AstraZeneca, Boehringer Ingelheim, Mesoblast, and AskBio, among others.

Cytokinetics has launched its first commercial drug, Myqorzo, in the United States and Germany following FDA and European Commission approvals for symptomatic obstructive hypertrophic cardiomyopathy. The U.S. rollout began in January 2026, with over 275 healthcare providers prescribing the drug and approximately 680 patients receiving it by the end of the first quarter, more than 70% of whom transitioned to paid prescriptions. The European Commission approved Myqorzo in February 2026, and the first EU launch occurred in Germany. The FDA has accepted a supplemental new drug application for Myqorzo as monotherapy, with a target action date of November 14, 2026, while the phase III ACACIA-HCM study in non-obstructive hypertrophic cardiomyopathy met both co-primary endpoints. Myqorzo competes with Bristol Myers Squibb's Camzyos and faces potential future competition from Edgewise Therapeutics' EDG-7500 and EDG-15400. Cytokinetics shares have gained 35.5% year to date, and the Zacks Consensus Estimate for 2026 loss per share has narrowed to $6.22.

Cytokinetics announced that three Late-Breaking Science abstracts have been accepted for the European Society of Cardiology Congress 2026, including a Hot Line presentation of primary results from ACACIA-HCM, the pivotal Phase 3 trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy. The Hot Line session is scheduled for August 28, with additional presentations on August 29 covering cardiac structure and function effects from ACACIA-HCM and aficamten versus metoprolol in obstructive HCM from the MAPLE-HCM trial. The company will host an investor event at the congress to discuss the findings, with details to be announced later.

Cytokinetics, Incorporated received a bullish thesis from TradersPro, highlighting the company's transition to a commercial-stage cardiovascular biopharmaceutical firm. Its lead drug Myqorzo, which treats adults with thickened-heart conditions that restrict blood flow, is now supported by global regulatory approvals in the United States, Europe, and China. Early physician adoption and positive trial readouts are expanding the drug's potential into related cardiac indications, while favorable demand dynamics are reinforced by aging populations and limited therapeutic competition. The stock, trading at $78.78 as of June 18th, is showing improving momentum with volume-supported price action, and 67 hedge fund portfolios held CYTK at the end of the first quarter, up from 58 in the previous quarter.